interview
Innovation for Parexel: A Right Mix of Driving Efficiency, Improving Quality, Lowering Cost, and Meeting Patients’ Needs
Peyton Howell Executive Vice President Chief Commercial & Strategy Officer Parexel International
Sanjay Vyas Senior Vice President, India Country Head & Managing Director & Global SBU Head - Clinical Trial Supplies & Logistics Parexel International
Being a Global name in CRO World, please walk us through Parexel’s business footprint. Peyton Howell: Parexel is one of the
largest Clinical Research Organizations (CRO) globally, with a 35-year history that includes being one of the first CRO organizations. The suite of biopharmaceutical services we provide to our clients across the globe ranges from clinical trials to regulatory, consulting, and market access to transform scientific discoveries into new treatments. Our 26 ◄ April 2020
In an exclusive in-person interaction with PharmaBio World, Peyton Howell – Chief Commercial & Strategy Officer of Parexel International and Sanjay Vyas – Senior Vice President, India Country Head & Managing Director; & Global SBU Head - Clinical Trial Supplies & Logistics, Parexel International speak about Parexel’s business footprint, expansion plans for Indian corridor, positioning over its contemporaries, regulatory guidelines, technology & innovation, patient-centricity, and many more intertwined aspects.
global regulatory expertise, Phase I-IV clinical research services, integrated e-Clinical technologies, and advanced commercialization services all work together to move our customers and through the development journey smoothly and cost-effectively from the beginning to the end. While we have dual headquarters near Boston, Massachusetts and in Durham, North Carolina, we work with clients in more than 100 countries across Asia, Europe, Middle East & Africa, North America, and South America.
What is your expansion plan for Indian Corridor? Sanjay Vyas: In the Indian Life-science
market over last 5 to 6 years, it’s evident that there has been double-digit growth in the range of 12 percent to 15 percent and we hope that Parexel will reflect that growth. India has been proved as a fastgrowing segment, country-wise, for us in terms of jobs, investments, and talent-pool. As a global clinical research provider, we consider India as a very important hub. Our Indian operation reflects Parexel globally, Pharma Bio World
